Histone deacetyases and DNA methyltransferases (DNMTs) are one of the targets that are recruited by RUNX1/ETO making HDAC and DNMT inhibitors a potential choice for targeting this sub-type of AML [83]. Here, RUNX1T1 is linked to acute myeloid leukemia.